Table 3

Multivariate analyses of engraftment and GVHD

End point: variableNumberHR (95% CI)P
ANC ≥ 500/mm3 during first 77 days after transplantation* (time unknown on 50 patients) 
    HLA mismatch and mismatch direction    
        0 MM 69 1.5 (1.1-2.0) .006 
        1-2 MM/GVHD only 57 1.6 (1.2-2.2) .003 
        1-2 MM/Rejection only 37 0.7 (0.4-1.1) .095 
        1 Bidirectional MM 342 1.0 (Reference)  
        2 Bidirectional MM 509 0.9 (0.8-1.1) .484 
        2 MM: Bidirectional + GVHD 80 0.9 (0.7-1.2) .588 
        2 MM: Bidirectional + rejection 53 0.8 (0.6-1.2) .304 
        2 MM: GVHD + rejection 5 0.9 (0.4-2.2) .806 
Platelet count ≥ 50 000/mm3 during first 9 mo after transplantation† (time unknown on 95 patients) 
    HLA mismatch and mismatch direction    
        0 MM 67 2.0(1.4-2.7) < 0.001 
        1-2 MM/GVHD only 54 1.6 (1.1-2.4) .009 
        1-2 MM/Rejection only 33 1.0 (0.6-1.7) .993 
        1 bidirectional MM 331 1.0 (Reference)  
        2 bidirectional MM 492 1.1 (0.9-1.3) .548 
        2 MM: bidirectional + GVHD 75 1.4 (0.9-2.1) .096 
        2 MM: bidirectional + rejection 50 1.1 (0.7-1.7) .666 
        2 MM: GVHD + rejection 5 1.4 (0.4-4.4) .566 
Acute grade 3-4 GVHD during first 150 d after transplantation among patients who engrafted‡ (data not reported on 61 patients) 
    HLA mismatch and mismatch direction    
        0 MM 58 0.3 (0.1-0.9) .022 
        1-2 MM/GVHD only 45 0.6 (0.3-1.4) .241 
        1-2 MM/rejection only 22 0.6 (0.2-1.8) .354 
        1 bidirectional MM 262 1.0 (Reference)  
        2 bidirectional MM 368 1.3 (0.97-1.9) .074 
        2 MM: bidirectional + GVHD 59 1.0 (0.5-1.7) .889 
        2 MM: bidirectional + rejection 38 0.7 (0.3-1.8) .505 
        2 MM: GVHD + rejection 5 0.0 (0.0- > >) .942 
Chronic GVHD during first 3 y after transplantation among patients who engrafted and survived to day 100§ (data not reported on 135 patients) 
    HLA mismatch and mismatch direction    
        0 MM 42 1.0 (0.6-1.9) .939 
        1-2 MM/GVHD only 35 1.2 (0.6-2.3) .591 
        1-2 MM/rejection only 13 0.9 (0.3-2.8) .811 
        1 bidirectional MM 162 1.0 (Reference)  
        2 bidirectional MM 208 1.3 (0.8-1.9) .256 
        2 MM: bidirectional + GVHD 36 1.6 (0.9-3.0) .103 
        2 MM: bidirectional + rejection 25 0.9 (0.4-2.2) .843 
        2 MM: GVHD + rejection 3 3.1 (0.7-12.9) .122 
End point: variableNumberHR (95% CI)P
ANC ≥ 500/mm3 during first 77 days after transplantation* (time unknown on 50 patients) 
    HLA mismatch and mismatch direction    
        0 MM 69 1.5 (1.1-2.0) .006 
        1-2 MM/GVHD only 57 1.6 (1.2-2.2) .003 
        1-2 MM/Rejection only 37 0.7 (0.4-1.1) .095 
        1 Bidirectional MM 342 1.0 (Reference)  
        2 Bidirectional MM 509 0.9 (0.8-1.1) .484 
        2 MM: Bidirectional + GVHD 80 0.9 (0.7-1.2) .588 
        2 MM: Bidirectional + rejection 53 0.8 (0.6-1.2) .304 
        2 MM: GVHD + rejection 5 0.9 (0.4-2.2) .806 
Platelet count ≥ 50 000/mm3 during first 9 mo after transplantation† (time unknown on 95 patients) 
    HLA mismatch and mismatch direction    
        0 MM 67 2.0(1.4-2.7) < 0.001 
        1-2 MM/GVHD only 54 1.6 (1.1-2.4) .009 
        1-2 MM/Rejection only 33 1.0 (0.6-1.7) .993 
        1 bidirectional MM 331 1.0 (Reference)  
        2 bidirectional MM 492 1.1 (0.9-1.3) .548 
        2 MM: bidirectional + GVHD 75 1.4 (0.9-2.1) .096 
        2 MM: bidirectional + rejection 50 1.1 (0.7-1.7) .666 
        2 MM: GVHD + rejection 5 1.4 (0.4-4.4) .566 
Acute grade 3-4 GVHD during first 150 d after transplantation among patients who engrafted‡ (data not reported on 61 patients) 
    HLA mismatch and mismatch direction    
        0 MM 58 0.3 (0.1-0.9) .022 
        1-2 MM/GVHD only 45 0.6 (0.3-1.4) .241 
        1-2 MM/rejection only 22 0.6 (0.2-1.8) .354 
        1 bidirectional MM 262 1.0 (Reference)  
        2 bidirectional MM 368 1.3 (0.97-1.9) .074 
        2 MM: bidirectional + GVHD 59 1.0 (0.5-1.7) .889 
        2 MM: bidirectional + rejection 38 0.7 (0.3-1.8) .505 
        2 MM: GVHD + rejection 5 0.0 (0.0- > >) .942 
Chronic GVHD during first 3 y after transplantation among patients who engrafted and survived to day 100§ (data not reported on 135 patients) 
    HLA mismatch and mismatch direction    
        0 MM 42 1.0 (0.6-1.9) .939 
        1-2 MM/GVHD only 35 1.2 (0.6-2.3) .591 
        1-2 MM/rejection only 13 0.9 (0.3-2.8) .811 
        1 bidirectional MM 162 1.0 (Reference)  
        2 bidirectional MM 208 1.3 (0.8-1.9) .256 
        2 MM: bidirectional + GVHD 36 1.6 (0.9-3.0) .103 
        2 MM: bidirectional + rejection 25 0.9 (0.4-2.2) .843 
        2 MM: GVHD + rejection 3 3.1 (0.7-12.9) .122 

CBU indicates cord blood unit; CI, confidence interval; GVHD, graft-versus-host disease; MM, mismatch; NIMA, noninherited maternal antigen; NYBC, New York Blood Center; HR, hazard ratio; and TNC, total nucleated cell.

*

Other significant predictors included in the multivariate model for time to ANC 500 were TNC dose (continuous log transformed), prior transplant (none vs allogeneic vs autologous vs unknown), preparatory regimen (myeloblative vs nonmyeloablative vs unknown), GVHD prophylaxis (cyclosporin and steroids vs any methotrexate vs any tacrolimus without methotrexate vs other without methotrexate vs unknown) and year of transplant (1993-2002 vs 2003-2006). Match between recipient and donor for noninherited maternal antigens (NIMAs) was forced into the model even when not significant.

†

Other significant predictors included in the model for time to platelet 50 000 were TNC dose (continuous log transformed), patient age (< 10 y vs ≥ 10 y), patient ethnicity (White vs other vs unknown), prior transplant (none vs allogeneic vs autologous vs unknown), preparatory regimen (myeloblative vs nonmyeloablative vs unknown), GVHD prophylaxis (cyclosporin and steroids vs any methotrexate vs any tacrolimus without methotrexate vs other without methotrexate vs unknown) and year of transplant (1993-2002 vs 2003-2006). NIMA match also was forced into the model even when not significant.

‡

Other significant predictors included in the model for acute GVHD were patient age (< 10 y vs ≥ 10 y), GVHD prophylaxis (cyclosporin and steroids vs any methotrexate vs any tacrolimus without methotrexate vs other without methotrexate vs unknown) and transplant center experience with NYBC CBUs (< 50 vs ≥ 50 patients transplanted). NIMA match also was forced into the model even when not significant.

§

Other significant predictors included in the model for chronic GVHD were patient age (< 10 y vs ≥ 10 y), patient ethnicity (White vs other vs unknown) and transplant center experience with NYBC CBUs (< 50 vs ≥ 50 patients transplanted). NIMA match also was forced into the model even when not significant.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal